KYORIN Pharmaceutical (4569) · InitiativeFirst statedLatest General Meetings of Shareholders (2026-06-12): "Other"
Worldwide Out-Licensing of KRP-M223 to Novartis
First written in FY2025. . Latest entry: 2026-06-12.
2entries
2years
1from disclosures
How it moved
Same theme, other companies
Worldwide exclusive licensing-out of KRP-M223 to NovartisA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- 2026-06-12OtherGeneral Meetings of Shareholders
「In March 2025, we out-licensed our internally discovered compound KRP-M223 to Novartis.」
The timing of the KRP-M223 out-licensing was corrected in the notice of convocation from March 2024 to March 2025. There was no new progress in the substance of the existing out-licensing matter. - FY2025First statedAnnual report
「In March of that year, we entered into a global license agreement with Novartis for KRP-M223, a compound created in-house, granting exclusive worldwide rights to develop, manufacture and commercialize it. The upfront payment received under the agreement, approximately ¥8.2 billion, was recorded as revenue for the consolidated fiscal year.」
Exclusive worldwide development, manufacturing and commercialization rights for KRP-M223 were granted to Novartis, and an upfront payment of approximately ¥8.2 billion was recorded as revenue.